What changed: EGFR-mutated non-small-cell lung cancer
Every dated change on the records linked to EGFR-mutated non-small-cell lung cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Trial result8Milestone9This record1
September 2026 · 1
2025 · 2
2024 · 2
2023 · 4
- 2023Trial resultFLAURA2FLAURA2 reported
PFS HR 0.
- 2023Trial resultMARIPOSAMARIPOSA reported
PFS HR 0.
- 2023Trial resultTROPION-Lung05TROPION-Lung05 reported
ORR 43.
- 2023MilestoneFLAURA2FLAURA2 and PAPILLON: chemotherapy added to osimertinib; amivantamab plus chemotherapy for exon 20
A milestone in how this cancer is treated.
2021 · 1
2020 · 3
- 2020Trial resultADAURAADAURA reported
OS HR 0.
- 2020Trial resultGefitinib vs gefitinib plus pemetrexed-carboplatin in EGFR-mutant lung cancer (Tata Memorial)Gefitinib vs gefitinib plus pemetrexed-carboplatin in EGFR-mutant lung cancer (Tata Memorial) reported
PFS 16 vs 8 months (HR 0.
- 2020MilestoneADAURAADAURA: three years of adjuvant osimertinib cuts recurrence by 83 percent
A milestone in how this cancer is treated.